Previous 10 | Next 10 |
Decibel Therapeutics ( NASDAQ: DBTX ), which is focused on hearing loss treatments, is up 25% in Tuesday morning trading after Eli Lilly ( NYSE: LLY ) said it would acquire fellow hearing therapy company Akouos ( NASDAQ: AKUS ) . One of Decibel's ( ...
Stocks have taken us on a wild ride this year. Every time the market looks to be recovering, it drops again. This back and forth could last for several more weeks or months as we're still dealing with various problems, including geopolitical tensions. It may be discouraging, but having a lo...
Regeneron ( NASDAQ: REGN ) shares slipped in the pre-market trading Monday after Evercore ISI downgraded the biotech to In Line from Outperform, citing the need for clarity over the company's prospects in ophthalmology led by Wet AMD medication Eylea. In September, REGN sa...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) on Friday said that a panel of the European Medicines Agency (EMA) recommended the expanded approval of Libtayo (cemiplimab) as a monotherapy to treat adult patients with recurrent or metastatic cervical cancer and d...
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer PR Newswire Recommendation based on a Phase 3 Libtayo trial that was first and only to demonstrate significantly improved survival compared to chemotherapy...
All the major U.S. indexes are in bear territory now, and many solid stocks have contributed to the market's downward tumble. But even during this rough year, some have been beating the market, and many of those outperformers can be found in the healthcare sector. Investors often favor that...
The U.S. Food and Drug Administration (FDA) granted priority review to Regeneron Pharmaceuticals ( NASDAQ: REGN ) and Bayer's ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) Eylea injection to treat Retinopathy of Prematurity (ROP) in preterm infants. ROP is an ...
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review PR Newswire ROP is a leading cause of childhood blindness worldwide TARRYTOWN, N.Y. , Oct. 12, 2022 /PRNewswire/ -- Regener...
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old PR Newswire A majority of children on Dupixent (up to 68% on a higher dose) achiev...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combinat...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...